阿斯利康首席执行官索里奥表示，制药商无需大规模收购即可实现增长

2026-10-06 05:27

AstraZeneca (AZN) CEO Pascal Soriot said that the British drugmaker can continue to grow past the end of the decade without engaging in a major acquisition.
"We absolutely have what we need," he told Bloomberg in an interview, adding that the company has a strong pipeline. "If everything was to work, we would completely explode our turnover post-2030."
He noted that the company projects a ~60% probability of success across all of its pipeline candidates.
Soriot's comments come after an August report that AstraZeneca had held talks to acquire Bristol Myers Squibb (BMY). The combined company would have had a market value of close to $400B.
Soriot said that he wants AstraZeneca to have a place in the lucrative obesity drugs market. He would like to see his company's offering differentiated by having a drug that not only addresses obesity but also comorbidities associated with it, such as diabetes, high blood pressure, and high cholesterol, in a single pill.

More on AstraZeneca